VivoSim Labs (FRA:4OR) EBIT: €-0.58 Mil (TTM As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.13
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs EBIT?

VivoSim Labs FRA:4OR 39 EBIT is €-0.58 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review.

VivoSim Labs's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €-2.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. VivoSim Labs's annualized ROC % for the quarter that ended in Dec. 2025 was -396.20%. VivoSim Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,255.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. VivoSim Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 150.65%.


VivoSim Labs  (FRA:4OR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

VivoSim Labs's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-9.392 * ( 1 - 0% )/( (2.915 + 1.826)/ 2 )
=-9.392/2.3705
=-396.20 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

VivoSim Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.18/( ( (0.802 + max(-0.858, 0)) + (0.66 + max(-1.026, 0)) )/ 2 )
=-9.18/( ( 0.802 + 0.66 )/ 2 )
=-9.18/0.731
=-1,255.81 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.027 + 0 + 0.752) - (0.956 + 0 + 0.681)
=-0.858

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.028 + 0 + 0.605) - (1.073 + 0 + 0.586)
=-1.026

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

VivoSim Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.58/-0.385
=150.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VivoSim Labs EBIT Related Terms


VivoSim Labs EBIT Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs EBIT Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.13 -10.42 -16.56 -13.50 -2.29

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.29 6.34 -2.46 -2.17 -2.30

FRA:4OR vs AZTR, GRI, BIXT: EBIT Comparison

For the Biotechnology subindustry, VivoSim Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's EV-to-EBIT falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-0.58 Mil mean?
VivoSim Labs (FRA:4OR) has a EBIT of €-0.58 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on VivoSim Labs.
Is VivoSim Labs' EBIT too high?
VivoSim Labs' current EBIT is €-0.58 Mil. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EBIT compare to AZTR and GRI?
VivoSim Labs' EBIT of €-0.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on VivoSim Labs. VivoSim Labs's current EBIT is €-0.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EBIT of €-0.58 Mil. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current EBIT is €-0.58 Mil. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EBIT is €-0.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.

Key valuation signals for FRA:4OR:

  • EBIT: €-0.58 Mil
  • GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.13
GF Value